71. MGMT PROMOTER METHYLATION IS A PROGNOSTIC BIOMARKER IN EGFR MUTANT LUNG ADENOCARCINOMA WITH BRAIN METASTASES

EGFR-mutant lung adenocarcinomas (EGFRm-LUAD) have a higher risk of brain metastasis (BM) development than non-mutant lesions regardless of cancer stage. BM development is a marker of tumor aggressiveness and has significant prognostic impact that leads to treatment failure. MGMT promoter methylatio...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neurooncol Adv
Autors principals: Mamatjan, Yasin, Zuccato, Jeffrey, Moraes, Fabio, Cabanero, Michael, Shali, Wumairehan, Weiss, Jessica, Tsao, Ming, Aldape, Kenneth, Shepherd, Frances, Zadeh, Gelareh
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Supplement Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7401348/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa073.058
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars